Q2 2025 · 13F-HR
Krensavage Asset Management, LLCholdings as filed
Filed 2025-08-15 · accession 0001609251-25-000006
$188,935
Reported value
15
Positions
2025-06-30
Period end
The Brief · Krensavage Asset Management, LLC · Q2 2025
AI · grounded in 13F
Krensavage Asset Management, LLC established a new position in UTHR worth $29,064. The fund also initiated new stakes in CAH for $22,469 and EXEL for $21,752. Additional new positions include JAZZ, ENTA, and SUPN. The fund ended the period with 15 positions and total AUM of $188,935.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 91307C102 | UTHR | UNITED THERAPEUTICS CORP | $29,064 | 15.4% | 101,146 | Common | SOLE |
| 14149Y108 | CAH | CARDINAL HEALTH INC | $22,469 | 11.9% | 133,745 | Common | SOLE |
| 30161Q104 | EXEL | EXELIXIS INC | $21,752 | 11.5% | 493,526 | Common | SOLE |
| G50871105 | JAZZ | JAZZ PHARMACEUTICALS PLC | $17,490 | 9.26% | 164,816 | Common | SOLE |
| 29251M106 | ENTA | ENANTA PHARMACEUTICALS INC | $15,985 | 8.46% | 2,114,444 | Common | SOLE |
| 868459108 | SUPN | SUPERNUS PHARMACEUTICALS INC | $14,889 | 7.88% | 472,376 | Common | SOLE |
| G4766E116 | INDV | INDIVIOR PLC | $14,364 | 7.60% | 974,474 | Common | SOLE |
| 37733W204 | GSK | GSK PLC-SPON ADR | $10,434 | 5.52% | 271,729 | Common | SOLE |
| G29687103 | AVDL | AVADEL PHARMACEUTICALS | $8,486 | 4.49% | 958,877 | Common | SOLE |
| 09075V102 | BNTX | BIONTECH SE-ADR | $7,813 | 4.14% | 73,382 | Common | SOLE |
| 80105N105 | SNY | SANOFI-ADR | $7,196 | 3.81% | 148,946 | Common | SOLE |
| 478160104 | JNJ | JOHNSON & JOHNSON | $6,110 | 3.23% | 40,000 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $5,946 | 3.15% | 207,822 | Common | SOLE |
| 921659108 | VNDA | VANDA PHARMACEUTICALS INC | $4,837 | 2.56% | 1,024,883 | Common | SOLE |
| 75886F107 | REGN | REGENERON PHARMACEUTICALS | $2,100 | 1.11% | 4,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.